Compare Novo Nordisk A/S (NVO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs BlackRock TCP Capital Corp — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M). The key difference: Novo Nordisk A/S is far larger — about 816.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (26.09%). Which is the better fit depends on your goals.
| NVO | TCPC | |
|---|---|---|
Market Cap | $220.53B | $270.17M |
Sector | Health | Financials |
52-Week High | $71.70 | $7.64 |
52-Week Low | $35.29 | $3.14 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | 26.09% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
